Illumina reported revenue of $4.1B in its most recent quarter, up 21.7% year-over-year. The data shows a consistent trend of strong double-digit revenue growth, with the last four quarters coming in at +21.7%, +15.6%, +19.4%, and +17.0%. Illumina's net margin has expanded significantly, rising from 20.3% a year ago to 26.8% in the latest quarter. This indicates the company is gaining pricing power and operational efficiency as its technology becomes more widely adopted. Illumina's robust revenue growth and margin expansion are being driven by the rapidly increasing adoption of next-generation sequencing (NGS) technology across the genomics ecosystem. The company is a leader in NGS platforms used for medical research, clinical diagnostics, and consumer genomics applications. Illumina's 13F institutional ownership has grown 32.5% quarter-over-quarter, signaling strong conviction from the smart money. Given Illumina's dominant market position, accelerating revenue growth, expanding margins, and increasing institutional investor support, I believe the stock has further upside potential. The company's technology appears well-positioned to capitalize on the multi-year trend of rising genomic sequencing adoption across healthcare and scientific research.

Research these companies